CN112939883B - 一种多取代1,3恶唑烷化合物的制备方法 - Google Patents
一种多取代1,3恶唑烷化合物的制备方法 Download PDFInfo
- Publication number
- CN112939883B CN112939883B CN201911177099.1A CN201911177099A CN112939883B CN 112939883 B CN112939883 B CN 112939883B CN 201911177099 A CN201911177099 A CN 201911177099A CN 112939883 B CN112939883 B CN 112939883B
- Authority
- CN
- China
- Prior art keywords
- polysubstituted
- preparation
- oxazolidine
- oxazolidine compound
- visible light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 polysubstituted 1, 3-oxazolidine compound Chemical class 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000003054 catalyst Substances 0.000 claims abstract description 13
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 claims abstract description 10
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940071870 hydroiodic acid Drugs 0.000 claims abstract description 9
- 150000002332 glycine derivatives Chemical class 0.000 claims abstract description 6
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims abstract description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 13
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 238000004440 column chromatography Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 6
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 10
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical class C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 6
- 238000003786 synthesis reaction Methods 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 3
- 239000002184 metal Substances 0.000 abstract description 3
- 229930014626 natural product Natural products 0.000 abstract description 3
- 239000011941 photocatalyst Substances 0.000 abstract description 3
- 230000002194 synthesizing effect Effects 0.000 abstract description 3
- 239000004593 Epoxy Chemical class 0.000 abstract description 2
- 230000000975 bioactive effect Effects 0.000 abstract description 2
- 239000000543 intermediate Substances 0.000 abstract description 2
- 230000003321 amplification Effects 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 238000011020 pilot scale process Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 7
- AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical compound C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 4
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005839 oxidative dehydrogenation reaction Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- ICVNPQMUUHPPOK-UHFFFAOYSA-N 2-(4-fluorophenyl)oxirane Chemical compound C1=CC(F)=CC=C1C1OC1 ICVNPQMUUHPPOK-UHFFFAOYSA-N 0.000 description 1
- FTVDOOKIZWBHOW-UHFFFAOYSA-N 2-(4-methylanilino)-1-phenylethanone Chemical compound C1=CC(C)=CC=C1NCC(=O)C1=CC=CC=C1 FTVDOOKIZWBHOW-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 238000010958 [3+2] cycloaddition reaction Methods 0.000 description 1
- CNUASVDRZNRMTH-UHFFFAOYSA-N [4-(oxiran-2-yl)phenyl] acetate Chemical compound C1=CC(OC(=O)C)=CC=C1C1OC1 CNUASVDRZNRMTH-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WCWSTNLSLKSJPK-LKFCYVNXSA-N cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- SDVWUMUCGZEZNB-UHFFFAOYSA-N ethyl 2-(4-bromoanilino)acetate Chemical compound CCOC(=O)CNC1=CC=C(Br)C=C1 SDVWUMUCGZEZNB-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002917 oxazolidines Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000007342 radical addition reaction Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006049 ring expansion reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D263/06—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
多取代1,3恶唑烷化合物具有广泛的药物活性,同时也属于有机制备范畴内的一类重要中间体,可以用于合成多种具有生物活性的天然产物和生物活性分子,具有很高的有机合成应用价值。本发明提供了一种极为简洁的可见光催化的1,3恶唑烷化合物的制备方法,具体过程为:以甘氨酸衍生物和环氧化合物为原料,以廉价的催化剂氢碘酸、氢溴酸或N‑溴代丁二酰亚胺为催化剂,在室温及可见光照射下反应10‑20h,分离纯化后得到一系列多取代1,3恶唑烷化合物。与现有技术相比,该制备方法具有步骤简洁、原料和催化剂廉价易得、无金属、无额外光催化剂、反应条件温和、反应操作简单等优点,更适合于中试放大与大规模制备多取代1,3恶唑烷化合物。
Description
技术领域
本发明属于有机化合物合成制备技术领域,尤其涉及了一种多取代1,3恶唑烷化合物的制备方法。
背景技术
多取代1,3恶唑烷是一种十分重要的五元氮杂环化合物,它不仅是很多天然产物和生物活性分子(如Erchinines A and B、(-)-Quinocarcin、GSK1265744等)的重要骨架,还可以作为有机合成中间体,参与复杂天然产物和活性功能分子的合成。此外,该结构骨架还可以作为不对称催化反应中的手性助剂和过渡金属催化反应中的配体而在化学反应中得以广泛应用。
已报道的合成多取代1,3恶唑烷类化合物的方法主要有:(1)氨基醇或氮杂环丙烷与醛酮的反应;(2)具有环张力的三元环或四元环的扩环反应;(3)过渡金属催化的偶极[3+2]环加成反应;(4)氧化剂作用下的氧化脱氢[2+3]环加成反应;(5)可见光催化下自由基加成环化反应等。
虽然构建恶唑烷骨架的方法已经被广泛研究,但已报道的策略通常具有起始原料复杂、反应条件苛刻以及须使用昂贵的金属催化剂等不足。这使得已报道方法的应用性受到了限制。
在此,本发明提供一种可见光催化的甘氨酸衍生物与环氧化合物间的氧化脱氢形式[2+3]环化反应来合成多取代1,3恶唑烷化合物的新方法。该方法以廉价、丰富、绿色的可见光作为能源,以空气中的氧气作为绿色氧化剂,此外,其还具有原料便宜易得、反应条件温和绿色、操作简便等优点,可以以70%-80%的产率高效地制备一系列多取代1,3恶唑烷类化合物。尤为重要的是,此反应无需额外的光催化剂,仅以廉价易得的氢碘酸、氢溴酸或N-溴代丁二酰亚胺为催化剂,大大降低了反应成本。
发明内容
本发明旨在提供一种反应条件温和、绿色、高效、成本低的多取代1,3恶唑烷类化合物的合成方法。
反应方程式如下式所示。
其中R1取代基可以是甲基、甲氧基等;R2取代基可以是烷氧基、苯基、取代氨基等;R3取代基可以是各种取代芳基等。
该制备过程主要包括以下步骤:向烧瓶中依次加入甘氨酸衍生物、环氧乙烷衍生物、催化剂和适量溶剂,在可见光照射下室温搅拌10-20小时,然后减压蒸除溶剂,柱层析得到多取代1,3恶唑烷化生物。
在上述步骤中,催化剂优选为氢碘酸、氢溴酸或N-溴代丁二酰亚胺其中一种。
在上述步骤中,可见光光源优选为26W节能灯、太阳光或5W蓝色LED灯其中一种。
在上述步骤中,溶剂优选为二氯甲烷、甲苯、1,2-二氯乙烷或1,2-二氯乙烷与乙腈的混合溶剂其中一种。
在上述步骤中,甘氨酸衍生物、环氧乙烷衍生物与催化剂的摩尔比优选为1:1.2:0.3。
在上述步骤中,反应过程中温度优选为室温。
与现有技术相比,本发明具有以下优点:
1.反应原料及催化剂廉价易得。
2.反应仅需一步转化,收率较好(70-80%)。
3.不使用额外的光催化剂、氧化剂以及金属试剂等,反应在室温、空气和可见光照射下进行,反应条件温和,操作简便,环境友好、绿色环保,克服了传统方法条件苛刻、原料或催化剂昂贵等缺点。
附图说明
图1为3-(4-甲氧基苯基)-4-苯基恶唑烷-2-羧酸乙酯的1H NMR图谱
图2为3-(4-甲氧基苯基)-4-苯基恶唑烷-2-羧酸乙酯的13C NMR图谱
具体实施方式
下面的实例可以使本专业的技术人员更了解本发明,但不以任何方式限制本发明。本发明所用原料均为已知化合物,可由市场购得或可采用本领域已知方法制备得到。
实施例1:3-(4-甲氧基苯基)-4-苯基恶唑烷-2-羧酸乙酯的制备
在100mL烧瓶中,将1.05g(5mmol)(4-甲氧基苯基)甘氨酸乙酯溶于50.0mL二氯甲烷,然后依次加入721mg(6mmol)氧化苯乙烯、253mg(30mol%)氢溴酸,在26W节能灯照射下室温搅拌12小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.31g产品,产率80%。淡黄色液体。1H NMR(400MHz,CDCl3)δ7.34–7.29(m,4H),7.27–7.22(m,1H),6.70(d,J=9.1Hz,2H),6.50(d,J=9.1Hz,2H),5.79(s,1H),4.98(dd,J=7.4,3.7Hz,1H),4.79(t,J=7.6Hz,1H),4.22–4.10(m,2H),4.01(dd,J=7.8,3.7Hz,1H),3.67(s,3H),1.20(t,J=7.1Hz,3H);13C NMR(100MHz,CDCl3)δ170.0,152.5,141.1,136.7,128.8,127.5,126.2,115.4,114.6,89.1,75.9,61.2,61.0,55.4,14.1.HRMS(ESI):calcd for C19H21NO4Na(M+Na+)350.1363;found 350.1369.
实施例2:(3-(4-甲氧基苯基)-4-苯基恶唑烷-2-羰基)甘氨酸乙酯的制备
在100mL烧瓶中,将1.33g(5mmol)(4-甲氧基苯基)甘氨酰甘氨酸乙酯溶于50.0mL1,2-二氯乙烷,然后依次加入721mg(6mmol)氧化苯乙烯、337mg(30mol%)氢碘酸,在5W蓝色LED灯照射下室温搅拌15小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=4:1)得到1.50g产品,产率78%。白色固体。1H NMR(400MHz,CDCl3)δ7.30–7.21(m,3H),7.16(d,J=6.9Hz,2H),7.06(s,1H),6.69(d,J=9.0Hz,2H),6.49(d,J=9.0Hz,2H),5.66(s,1H),5.05(d,J=4.6Hz,1H),4.59(dd,J=8.1,6.2Hz,1H),4.20–4.08(m,3H),4.04(dd,J=8.2,1.7Hz,1H),3.94(dd,J=18.3,4.9Hz,1H),3.65(s,3H),1.25(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ169.41,169.37,152.5,140.3,136.3,128.7,127.5,126.6,115.7,114.5,89.3,74.6,61.7,61.5,55.3,41.0,14.0.HRMS-ESI:calcd for C21H24N2O5(M+H)+385.1758,found 385.1765.
实施例3:苯基(4-苯基-3-(对甲苯基)恶唑烷-2-基)甲酮的制备
在100mL烧瓶中,将1.13g(5mmol)1-苯基-2-(对甲苯胺基)乙-1-酮溶于50.0mL甲苯,然后依次加入721mg(6mmol)氧化苯乙烯、267mg(30mol%)N-溴代丁二酰亚胺,在5W蓝色LED灯照射下室温搅拌20小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.36g产品,产率79%。黄色固体。1H NMR(400MHz,CDCl3)δ8.13(d,J=7.5Hz,2H),7.64–7.60(m,1H),7.53–7.49(m,2H),7.36–7.31(m,4H),7.27–7.24(m,1H),6.85(d,J=8.3Hz,2H),6.68(s,1H),6.26(d,J=8.4Hz,2H),5.08(dd,J=7.1,1.9Hz,1H),4.47(t,J=7.7Hz,1H),4.04(dd,J=8.3,2.0Hz,1H),2.13(s,3H).13C NMR(100MHz,CDCl3)δ194.3,142.1,140.8,134.9,133.7,129.7,128.9,128.8,127.5,126.7,126.2,113.4,88.3,75.1,61.5,20.2.HRMS-ESI:calcd for C23H21NO2(M+H)+344.1645,found 344.1652.
实施例4:3-(3-氟-4-甲基苯基)-4-苯基恶唑烷-2-羧酸乙酯的制备
在100mL烧瓶中,将1.06g(5mmol)(3-氟-4-甲基苯基)甘氨酸乙酯溶于50.0mL(1,2-二氯乙烷/乙腈=15:1),然后依次加入721mg(6mmol)氧化苯乙烯、337mg(30mol%)氢碘酸,在26W节能灯照射下室温搅拌20小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.17g产品,产率71%。淡棕色液体。1H NMR(400MHz,CDCl3)δ7.34–7.30(m,2H),7.29–7.23(m,3H),6.91–6.87(m,1H),6.23–6.16(m,2H),5.74(s,1H),4.95(dd,J=7.2,2.7Hz,1H),4.79(t,J=7.6Hz,1H),4.27–4.16(m,2H),4.04(dd,J=8.0,2.7Hz,1H),2.08(s,3H),1.26(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ169.6,161.6(d,JC-F=241.3Hz),142.1(d,JC-F=10.5Hz),141.0,131.7(d,JC-F=7.0Hz),128.9,127.7,126.1,114.0(d,JC-F=17.5Hz),109.2,101.1(d,JC-F=27.1Hz),88.4,75.7,61.5,61.0,14.1,13.5(d,JC-F=3.2Hz).19F NMR(376MHz,CDCl3)δ-115.86(s,F).HRMS-ESI:calcd for C19H20FNO3(M+H)+330.1500,found 330.1508.
实施例5:3-(4-溴苯基)-4-苯基恶唑烷-2-羧酸乙酯的制备
在100mL烧瓶中,将1.29g(5mmol)(4-溴苯基)甘氨酸乙酯溶于50.0mL(1,2-二氯乙烷/乙腈=20:1),然后依次加入721mg(6mmol)氧化苯乙烯、337mg(30mol%)氢碘酸,在5W蓝色LED灯照射下室温搅拌15小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.35g产品,产率72%。淡黄色液体。1H NMR(400MHz,CDCl3)δ7.33–7.24(m,5H),7.20(d,J=9.0Hz,2H),6.38(d,J=9.0Hz,2H),5.76(s,1H),4.96(dd,J=7.2,2.6Hz,1H),4.80(dd,J=8.0,7.2Hz,1H),4.25–4.17(m,2H),4.05(dd,J=8.1,2.7Hz,1H),1.26(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ169.4,141.5,140.7,131.9,128.9,127.8,126.1,115.3,110.5,88.2,75.7,61.6,60.9,14.1.HRMS-ESI:calcd for C18H18BrNO3(M+Na)+398.0362,found398.0372.
实施例6:4-(4-氟苯基)-3-(4-甲氧基苯基)恶唑烷-2-羧酸乙酯的制备
在100mL烧瓶中,将1.05g(5mmol)(4-甲氧基苯基)甘氨酸乙酯溶于50.0mL(1,2-二氯乙烷/乙腈=25:1),然后依次加入828mg(6mmol)(4-氟苯基)环氧乙烷、337mg(30mol%)氢碘酸,在太阳光照射下室温搅拌10小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.33g产品,产率77%。淡棕色液体。1H NMR(400MHz,CDCl3)δ7.32–7.25(m,2H),7.03–6.95(m,2H),6.71(d,J=9.0Hz,2H),6.49(d,J=9.0Hz,2H),5.78(s,1H),4.97(dd,J=7.4,3.7Hz,1H),4.77(t,J=7.6Hz,1H),4.21–4.11(m,2H),3.98(dd,J=7.9,3.6Hz,1H),3.68(s,3H),1.20(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ169.9,162.1(d,JC-F=244.1Hz),152.6,136.8(d,JC-F=2.9Hz),136.4,127.8(d,JC-F=8.0Hz),115.7(d,JC-F=21.4Hz),115.5,114.6,89.1,75.8,61.3,60.3,55.4,14.1.19F NMR(376MHz,CDCl3)δ-114.87(s,F).HRMS-ESI:calcd for C19H20FNO4(M+H)+346.1449,found 346.1450.
实施例7:4-(4-乙酰氧基苯基)-3-(4-甲氧基苯基)恶唑烷-2-羧酸乙酯的制备
在100mL烧瓶中,将1.05g(5mmol)(4-甲氧基苯基)甘氨酸乙酯溶于50.0mL(1,2-二氯乙烷/乙腈=20:1),然后依次加入1.07g(6mmol)(4-乙酰氧基苯基)环氧乙烷、337mg(30mol%)氢碘酸,在5W蓝色LED灯照射下室温搅拌16小时。然后减压蒸除溶剂,柱层析(石油醚/乙酸乙酯=16:1)得到1.39g产品,产率72%。淡棕色液体。1H NMR(400MHz,CDCl3)δ7.32(d,J=8.5Hz,2H),7.04(d,J=8.5Hz,2H),6.71(d,J=9.0Hz,2H),6.50(d,J=9.0Hz,2H),5.78(s,1H),4.98(dd,J=7.4,3.6Hz,1H),4.77(t,J=7.6Hz,1H),4.20–4.10(m,2H),4.01(dd,J=7.9,3.6Hz,1H),3.68(s,3H),2.27(s,3H),1.20(t,J=7.1Hz,3H).13C NMR(100MHz,CDCl3)δ169.9,169.3,152.6,149.9,138.6,136.5,127.3,121.9,115.5,114.6,89.1,75.7,61.2,60.4,55.4,21.0,14.0.HRMS-ESI:calcd for C21H23NO6(M+H)+386.1598,found386.1599.
Claims (3)
1.一种多取代1,3恶唑烷化合物的制备方法,其特征在于具体步骤为:向烧瓶中依次加入如Ⅰ所示的甘氨酸衍生物、如Ⅱ所示的环氧乙烷衍生物、催化剂和适量溶剂,在可见光照射下于室温搅拌10-20小时,然后减压蒸除溶剂,柱层析得到多取代1,3恶唑烷化合物,制备过程如下所示:
其中R1取代基是甲基、甲氧基;R2取代基是烷氧基、苯基、取代氨基;R3取代基是取代芳基;催化剂为氢碘酸、氢溴酸或N-溴代丁二酰亚胺其中一种;溶剂为二氯甲烷、甲苯、1,2-二氯乙烷或1,2-二氯乙烷与乙腈的混合溶剂其中一种。
2.根据权利要求1所述的多取代1,3恶唑烷化合物的制备方法,其特征在于:可见光光源为26W节能灯、太阳光或5W蓝色LED灯其中一种。
3.根据权利要求1所述的多取代1,3恶唑烷化合物的制备方法,其特征在于:甘氨酸衍生物、环氧乙烷衍生物与催化剂的摩尔比为1:1.2:0.3。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911177099.1A CN112939883B (zh) | 2019-11-26 | 2019-11-26 | 一种多取代1,3恶唑烷化合物的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911177099.1A CN112939883B (zh) | 2019-11-26 | 2019-11-26 | 一种多取代1,3恶唑烷化合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112939883A CN112939883A (zh) | 2021-06-11 |
CN112939883B true CN112939883B (zh) | 2024-01-16 |
Family
ID=76225228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911177099.1A Active CN112939883B (zh) | 2019-11-26 | 2019-11-26 | 一种多取代1,3恶唑烷化合物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112939883B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115611879A (zh) * | 2022-11-07 | 2023-01-17 | 曲阜师范大学 | 一种恶唑衍生物及其合成方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866567A (zh) * | 2017-03-06 | 2017-06-20 | 南京大学 | 氟代恶唑烷酮类化合物的合成方法 |
CN107365278A (zh) * | 2017-06-09 | 2017-11-21 | 衢州英特高分子材料有限公司 | 一种多取代异恶唑烷衍生物及其制备方法 |
-
2019
- 2019-11-26 CN CN201911177099.1A patent/CN112939883B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106866567A (zh) * | 2017-03-06 | 2017-06-20 | 南京大学 | 氟代恶唑烷酮类化合物的合成方法 |
CN107365278A (zh) * | 2017-06-09 | 2017-11-21 | 衢州英特高分子材料有限公司 | 一种多取代异恶唑烷衍生物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
Nepenthe-Like Indole Alkaloids with Antimicrobial Activity from Ervatamia chinensis;Hao-Fei Yu 等;Org.Lett.;第第20卷卷;第4116-4120页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112939883A (zh) | 2021-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yuan et al. | Phosphine-catalyzed [4+ 2] cyclization of para-quinone methide derivatives with allenes | |
CN107805232B (zh) | 一种含甲硫基呋喃衍生物的合成方法 | |
CN108003086B (zh) | 一种3-胺基-2-吲哚酮类化合物的制备方法 | |
CN112939883B (zh) | 一种多取代1,3恶唑烷化合物的制备方法 | |
CN115947668A (zh) | 一种多取代茚衍生物的制备方法 | |
CN110372611B (zh) | 一种选择性合成多取代二氢喹唑啉酮或喹唑啉酮的方法 | |
CN108976243B (zh) | 通过二甲基呋喃与含氧化吲哚邻羟基苄醇合成螺-色满-4,3′-氧化吲哚的合成方法 | |
Yan et al. | Unexpected TFA-catalyzed tandem reaction of benzo [d] oxazoles with 2-oxo-2-arylacetic acids: synthesis of 3-aryl-2 H-benzo [b][1, 4] oxazin-2-ones and cephalandole A | |
CN112442008B (zh) | 一种温度调控单质硫与活泼内炔制备1,4-二噻烯和噻吩类化合物的方法及其转化反应 | |
CN112174842B (zh) | 一种制备(s)-3-氨基-2-苄基丙酸的方法 | |
CN113861137B (zh) | 酮与alpha氯代酮一步反应合成呋喃类化合物的方法 | |
CN101343263B (zh) | 一种合成5-硝基-4,5-二氢呋喃衍生物的方法 | |
CN112939903B (zh) | 一种由溴代芳酮制备呋喃类化合物的方法 | |
CN101628904B (zh) | 一种合成2-硝基-3-芳基-2,3,5,7-四氢苯并呋喃-4-酮衍生物的方法 | |
CN111362973B (zh) | 一种1,2-苯并噻嗪衍生物的合成方法 | |
CN108610306B (zh) | 一种2h-1,4-噻嗪-3(4h)-酮衍生物的合成方法 | |
CN109320488B (zh) | 一种3-羟基黄酮及其衍生物的水相一锅合成方法 | |
CN113651788A (zh) | 一种3-胺烷基色酮化合物及其制备方法 | |
CN104860911A (zh) | 一种手性3,4-二氢香豆素衍生化合物合成方法 | |
CN107686460B (zh) | 一种3-取代-3-羟基-2-吲哚酮类化合物的制备方法 | |
CN109833908A (zh) | 一种手性高价碘催化剂及其制备方法和应用 | |
CN111100085A (zh) | 一种3-芳基-2H-苯并[β][1,4]苯并恶嗪-2-酮化合物的制备方法 | |
CN104817483A (zh) | 一种双羰基吲哚类化合物及其合成方法 | |
CN106854191B (zh) | 2-位含有手性季碳中心的3-亚甲基-2,3-二氢呋喃的合成方法 | |
CN113149923B (zh) | 3-氰基-n-氧化异噁唑啉类化合物及其合成方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |